Physician profile
Peter Ngo
NPI 1245626647
$2,458.13
in general payments reported to CMS, 2019-2025
34 companies · $235 in 2025
The $235 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.21 · 2020: $99.48 · 2022: $297 · 2023: $667 · 2024: $1,073 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,787 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,787.00 |
| Education | $188.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $242.43 | 2022-2025 | Reblozyl |
| Emd Serono, INC. | $233.21 | 2023-2024 | Bavencio |
| E.R. Squibb & Sons, L.L.C. | $192.77 | 2023-2025 | Reblozyl, Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $172.29 | 2022-2024 | Enhertu, Lynparza |
| Regeneron Healthcare Solutions, INC. | $160.20 | 2024 | Libtayo |
| Lilly USA, LLC | $151.17 | 2023-2025 | Verzenio, Jaypirca |
| Seagen INC. | $108.92 | 2022-2023 | Adcetris, Tukysa |
| Gilead Sciences, INC. | $99.99 | 2024 | Trodelvy |
| Btg International INC. | $99.48 | 2020 | |
| Rigel Pharmaceuticals, INC. | $87.06 | 2023 | Tavalisse, Rezlidhia |
| Novartis Pharmaceuticals Corporation | $86.21 | 2019 | |
| Daiichi Sankyo INC. | $75.74 | 2022-2024 | Enhertu |
| Karyopharm Therapeutics INC. | $60.70 | 2023-2024 | Xpovio |
| Exelixis INC. | $58.80 | 2023-2024 | Cabometyx |
| Janssen Biotech, INC. | $53.31 | 2022-2023 | Tecvayli |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $52.60 | 2024-2025 | Tecentriq |
| Deciphera Pharmaceuticals INC. | $50.73 | 2024 | Qinlock |
| Genzyme Corporation | $41.46 | 2023-2024 | |
| Pharmaessentia USA Corporation | $34.46 | 2024 | Besremi |
| Astellas Pharma US INC | $33.23 | 2024 | Xospata |
| Immunogen, INC. | $32.36 | 2023 | Elahere |
| Ipsen Biopharmaceuticals, INC | $31.59 | 2024 | Onivyde, Somatuline Depot |
| Incyte Corporation | $28.99 | 2022 | |
| Eisai INC. | $28.41 | 2022 | |
| Alexion Pharmaceuticals, INC. | $28.16 | 2023 | |
| X4 Pharmaceuticals, INC. | $28.10 | 2024 | Xolremdi |
| Adc Therapeutics America, INC. | $27.52 | 2024 | |
| Pfizer INC. | $27.15 | 2023 | |
| Servier Pharmaceuticals LLC | $24.99 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.49 | 2023 | |
| Morphosys, US INC. | $22.22 | 2023 | Monjuvi |
| Aveo Pharmaceuticals, INC. | $21.37 | 2023 | Fotivda |
| Mirati Therapeutics, INC. | $19.88 | 2024 | Krazati |
| Abbvie INC. | $18.14 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.